Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 139
Filtrar
1.
J Thromb Haemost ; 15(5): 983-997, 2017 05.
Artículo en Inglés | MEDLINE | ID: mdl-28296036

RESUMEN

Essentials CpG oligodeoxynucleotide (ODN) immuotherapeutics cause undesired platelet activating effects. It is crucial to understand the mechanisms of these effects to identify protective strategies. CpG ODN-induced platelet activation depends on C-type lectin-like receptor 2 (CLEC-2) and P2Y12. Targeting CLEC-2 or P2Y12 fully prevents CpG ODN-induced platelet activation and thrombosis. SUMMARY: Background Synthetic phosphorothioate-modified CpG oligodeoxynucleotides (ODNs) show potent immunostimulatory properties that are widely exploited in clinical trials of anticancer treatment. Unexpectedly, a recent study indicated that CpG ODNs activate human platelets via the immunoreceptor tyrosine-based activation motif (ITAM)-coupled receptor glycoprotein VI. Objective To further analyze the mechanisms of CpG ODN-induced platelet activation and identify potential inhibitory strategies. Methods In vitro analyses were performed on human and mouse platelets, and on cell lines expressing platelet ITAM receptors. CpG ODN platelet-activating effects were evaluated in a mouse model of thrombosis. Results We demonstrated platelet uptake of CpG ODNs, resulting in platelet activation and aggregation. C-type lectin-like receptor 2 (CLEC-2) expressed in DT40 cells bound CpG ODNs. CpG ODN uptake did not occur in CLEC-2-deficient mouse platelets. Inhibition of human CLEC-2 with a blocking antibody inhibited CpG ODN-induced platelet aggregation. CpG ODNs caused CLEC-2 dimerization, and provoked its internalization. They induced dense granule release before the onset of aggregation. Accordingly, pretreating platelets with apyrase, or inhibiting P2Y12 with cangrelor or clopidogrel, prevented CpG ODN platelet-activating effect. In vivo, intravenously injected CpG ODN interacted with platelets adhered to mouse injured endothelium, and promoted thrombus growth, which was inhibited by CLEC-2 deficiency or by clopidogrel. Conclusions CLEC-2 and P2Y12 are required for CpG ODN-induced platelet activation and thrombosis, and might be targeted to prevent adverse events in patients at risk.


Asunto(s)
Anticuerpos/farmacología , Plaquetas/efectos de los fármacos , Lectinas Tipo C/metabolismo , Glicoproteínas de Membrana/metabolismo , Oligonucleótidos Fosforotioatos/toxicidad , Activación Plaquetaria/efectos de los fármacos , Inhibidores de Agregación Plaquetaria/farmacología , Antagonistas del Receptor Purinérgico P2Y/farmacología , Receptores Purinérgicos P2Y12/efectos de los fármacos , Adyuvantes Inmunológicos/metabolismo , Adyuvantes Inmunológicos/toxicidad , Animales , Plaquetas/inmunología , Plaquetas/metabolismo , Línea Celular , Modelos Animales de Enfermedad , Humanos , Motivo de Activación del Inmunorreceptor Basado en Tirosina , Lectinas Tipo C/deficiencia , Lectinas Tipo C/inmunología , Masculino , Glicoproteínas de Membrana/deficiencia , Glicoproteínas de Membrana/inmunología , Ratones , Ratones Endogámicos C57BL , Oligonucleótidos Fosforotioatos/inmunología , Oligonucleótidos Fosforotioatos/metabolismo , Agregación Plaquetaria/efectos de los fármacos , Glicoproteínas de Membrana Plaquetaria/metabolismo , Unión Proteica , Receptores Purinérgicos P2Y12/metabolismo , Transducción de Señal/efectos de los fármacos , Trombosis/sangre , Trombosis/inmunología , Trombosis/prevención & control , Factores de Tiempo
2.
Toxicon ; 108: 240-8, 2015 Dec 15.
Artículo en Inglés | MEDLINE | ID: mdl-26528579

RESUMEN

Hemorrhage is one of the most striking effects of bites by viper snakes resulting in fast bleeding and ischemia in affected tissues. Snake venom metalloproteinases (SVMPs) are responsible for hemorrhagic activity, but the mechanisms involved in SVMP-induced hemorrhage are not entirely understood and the study of such mechanisms greatly depends on in vivo experiments. In vivo, hemorrhagic SVMPs accumulate on basement membrane (BM) of venules and capillary vessels allowing the hydrolysis of collagen IV with consequent weakness and rupture of capillary walls. These effects are not reproducible in vitro with conventional endothelial cell cultures. In this study we used two-dimension (2D) or three-dimension (3D) cultures of HUVECs on matrigel and observed the same characteristics as in ex vivo experiments: only the hemorrhagic toxin was able to localize on surfaces or internalize endothelial cells in 2D cultures or in the surface of tubules formed on 3D cultures. The contribution of matrigel, fibronectin and collagen matrices in jararhagin-induced endothelial cell damage was then analyzed. Collagen and matrigel substrates enhanced the endothelial cell damage induced by jararhagin allowing toxin binding to focal adhesions, disruption of stress fibers, detachment and apoptosis. The higher affinity of jararhagin to collagen than to fibronectin explains the localization of the toxin within BM. Moreover, once located in BM, interactions of jararhagin with α2ß1 integrin would favor its localization on focal adhesions, as observed in our study. The accumulation of toxin in focal adhesions, observed only in cells grown in collagen matrices, would explain the enhancement of cell damage in these matrices and reflects the actual interaction among toxin, endothelial cells and BM components that occurs in vivo and results in the hemorrhagic lesions induced by viper venoms.


Asunto(s)
Colágeno/efectos de los fármacos , Venenos de Crotálidos/farmacología , Fibronectinas/efectos de los fármacos , Metaloendopeptidasas/farmacología , Apoptosis/efectos de los fármacos , Membrana Basal/efectos de los fármacos , Técnicas de Cultivo de Célula , Uniones Célula-Matriz/efectos de los fármacos , Venenos de Crotálidos/análisis , Fragmentación del ADN/efectos de los fármacos , Combinación de Medicamentos , Células Endoteliales/efectos de los fármacos , Citometría de Flujo , Adhesiones Focales/efectos de los fármacos , Células Endoteliales de la Vena Umbilical Humana , Laminina , Metaloendopeptidasas/análisis , Modelos Biológicos , Proteoglicanos , Veneno de Bothrops Jararaca
3.
J Thromb Haemost ; 12(4): 550-9, 2014 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-24460629

RESUMEN

BACKGROUND: The activation of platelet CLEC-2 by podoplanin on lymphatic endothelial cells (LECs) has a critical role in prevention of mixing of lymphatic and blood vasculatures during embryonic development. Paradoxically, LECs release cAMP and cGMP-elevating agents, prostacyclin (PGI2 ) and nitric oxide (NO), respectively, which are powerful inhibitors of platelet activation. This raises the question of how podoplanin is able to activate CLEC-2 in the presence of the inhibitory cyclic nucleotides. OBJECTIVES: We investigated the influence of cyclic nucleotides on CLEC-2 signaling in platelets. METHODS: We used rhodocytin, CLEC-2 monoclonal antibody, LECs and recombinant podoplanin as CLEC-2 agonists on mouse platelets. The effects of the cyclic nucleotide-elevating agents PGI2 , forskolin and the NO-donor GSNO were assessed with light transmission aggregometry, flow cytometry, protein phosphorylation and fluorescent imaging of platelets on LECs. RESULTS: We show that platelet aggregation induced by CLEC-2 agonists is resistant to GSNO but inhibited by PGI2 . The effect of PGI2 is mediated through decreased phosphorylation of CLEC-2, Syk and PLCγ2. In contrast, adhesion and spreading of platelets on recombinant podoplanin, CLEC-2 antibody and LECs is not affected by PGI2 and GSNO. Consistent with this, CLEC-2 activation of Rac, which is required for platelet spreading, is not altered in the presence of PGI2 . CONCLUSIONS: The present results demonstrate that platelet adhesion and activation on CLEC-2 ligands or LECs is maintained in the presence of PGI2 and NO.


Asunto(s)
Plaquetas/citología , AMP Cíclico/metabolismo , GMP Cíclico/metabolismo , Lectinas Tipo C/metabolismo , Glicoproteínas de Membrana/metabolismo , Activación Plaquetaria , Animales , Plaquetas/efectos de los fármacos , Calcio/metabolismo , Adhesión Celular , Epoprostenol/metabolismo , Ratones , Ratones Endogámicos C57BL , Óxido Nítrico/metabolismo , Adhesividad Plaquetaria , Agregación Plaquetaria , Venenos de Víboras/metabolismo
4.
Aquat Conserv ; 22(2): 232-261, 2012 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-25505830

RESUMEN

The Chagos Archipelago was designated a no-take marine protected area (MPA) in 2010; it covers 550 000 km2, with more than 60 000 km2 shallow limestone platform and reefs. This has doubled the global cover of such MPAs.It contains 25-50% of the Indian Ocean reef area remaining in excellent condition, as well as the world's largest contiguous undamaged reef area. It has suffered from warming episodes, but after the most severe mortality event of 1998, coral cover was restored after 10 years.Coral reef fishes are orders of magnitude more abundant than in other Indian Ocean locations, regardless of whether the latter are fished or protected.Coral diseases are extremely low, and no invasive marine species are known.Genetically, Chagos marine species are part of the Western Indian Ocean, and Chagos serves as a 'stepping-stone' in the ocean.The no-take MPA extends to the 200 nm boundary, and. includes 86 unfished seamounts and 243 deep knolls as well as encompassing important pelagic species.On the larger islands, native plants, coconut crabs, bird and turtle colonies were largely destroyed in plantation times, but several smaller islands are in relatively undamaged state.There are now 10 'important bird areas', coconut crab density is high and numbers of green and hawksbill turtles are recovering.Diego Garcia atoll contains a military facility; this atoll contains one Ramsar site and several 'strict nature reserves'. Pollutant monitoring shows it to be the least polluted inhabited atoll in the world. Today, strict environmental regulations are enforced.Shoreline erosion is significant in many places. Its economic cost in the inhabited part of Diego Garcia is very high, but all islands are vulnerable.Chagos is ideally situated for several monitoring programmes, and use is increasingly being made of the archipelago for this purpose.

6.
J Thromb Haemost ; 7(7): 1192-9, 2009 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-19422460

RESUMEN

BACKGROUND: Syk is a key mediator of signaling pathways downstream of several platelet surface receptors including GPVI/FcRgamma collagen receptor, the C-type lectin receptor CLEC-2, and integrin alphaIIbbeta3. A recent study identified the novel small molecule R406 as a selective inhibitor of Syk. OBJECTIVES: The present study evaluates the role of Syk in human platelets using the novel inhibitor R406. METHODS: Agonist-induced GPVI and CLEC-2 signaling were assessed using aggregometry, immunoprecipitation and western blotting to determine the effects of R406 on platelet activation. RESULTS: We demonstrate R406 to be a powerful inhibitor of Syk in human platelets. R406 abrogated shape change and aggregation induced by activation of GPVI and CLEC-2, and reduced platelet spreading on fibrinogen. The inhibitory effect of R406 was associated with inhibition of tyrosine phosphorylation of signaling proteins that lay downstream of Syk for all three receptors, including PLCgamma2. Strikingly, R406 markedly inhibited tyrosine phosphorylation of CLEC-2 and Syk downstream of CLEC-2 activation, whereas phosphorylation of Syk downstream of GPVI and integrin alphaIIbbeta3 was unaffected. CONCLUSIONS: The inhibitory effect of R406 provides direct evidence of a role for Syk in GPVI, CLEC-2 and integrin alphaIIbbeta3 signaling in human platelets. Further, the results demonstrate a critical role for Syk in mediating tyrosine phosphorylation of CLEC-2, suggesting a novel model in which both Src and Syk kinases regulate tyrosine phosphorylation of the C-type lectin receptor leading to platelet activation.


Asunto(s)
Plaquetas/efectos de los fármacos , Péptidos y Proteínas de Señalización Intracelular/antagonistas & inhibidores , Lectinas Tipo C/metabolismo , Glicoproteínas de Membrana/metabolismo , Oxazinas/farmacología , Glicoproteínas de Membrana Plaquetaria/metabolismo , Inhibidores de Proteínas Quinasas/farmacología , Proteínas Tirosina Quinasas/antagonistas & inhibidores , Piridinas/farmacología , Transducción de Señal/efectos de los fármacos , Plaquetas/enzimología , Western Blotting , Humanos , Inmunoprecipitación , Quinasa Syk
7.
J Thromb Haemost ; 6(12): 2152-9, 2008 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-18826392

RESUMEN

BACKGROUND: The adapter proteins SLP-76 and LAT have been shown to play critical roles in the activation of PLCgamma2 in platelets downstream of GPVI/FcRgamma and the C-type lectin receptor CLEC-2. SLP-76 is constitutively associated with the adapter Gads in platelets, which also binds to tyrosine phosphorylated LAT, thereby providing a potential pathway of regulation of SLP-76. OBJECTIVE: In the present study, we have compared the role of Gads alongside that of LAT following activation of the major platelet glycoprotein receptors using mice deficient in the two adapter proteins. RESULTS: Gads was found to be required for the efficient onset of aggregation and secretion in response to submaximal stimulation of GPVI and CLEC-2, but to be dispensable for activation following stronger stimulation of the two receptors. Gads was also dispensable for spreading induced through integrin alpha(IIb)beta(3) or the GPIb-IX-V complex. Further, Gads plays a negligible role in aggregate formation on collagen at an arteriolar rate of shear. In stark contrast, platelets deficient in the adapter LAT exhibit a marked decrease in aggregation and secretion following activation of GPVI and CLEC-2, and are unable to form stable aggregates on collagen at arteriolar shear. CONCLUSIONS: The results demonstrate that Gads plays a key role in linking the adapter LAT to SLP-76 in response to weak activation of GPVI and CLEC-2 whereas LAT is required for full activation over a wider range of agonist concentrations. These results reveal the presence of a Gads-independent pathway of platelet activation downstream of LAT.


Asunto(s)
Proteínas Adaptadoras Transductoras de Señales/fisiología , Lectinas Tipo C/fisiología , Proteínas de la Membrana/fisiología , Fosfoproteínas/fisiología , Activación Plaquetaria , Glicoproteínas de Membrana Plaquetaria/fisiología , Animales , Plaquetas/metabolismo , Ratones , Ratones Noqueados , Transducción de Señal
8.
Biochimie ; 90(3): 484-92, 2008 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-18096518

RESUMEN

Snake venom metalloproteinases (SVMPs) are multifunctional enzymes involved in several symptoms following snakebite, such as severe local hemorrhage. Multidomain P-III SVMPs are strongly hemorrhagic, whereas single domain P-I SVMPs are not. This indicates that disintegrin-like and cysteine-rich domains allocate motifs that enable catalytic degradation of ECM components leading to disruption of capillary vessels. Interestingly, some P-III SVMPs are completely devoid of hemorrhagic activity despite their highly conserved disintegrin-like and cysteine-rich domains. This observation was approached in the present study by comparing the effects of jararhagin, a hemorrhagic P-III SVMP, and berythractivase, a pro-coagulant and non-hemorrhagic P-III SVMP. Both toxins inhibited collagen-induced platelet aggregation, but only jararhagin was able to bind to collagen I with high affinity. The monoclonal antibody MAJar 3, that neutralizes the hemorrhagic effect of Bothrops venoms and jararhagin binding to collagen, did not react with berythractivase. The three-dimensional structures of jararhagin and berythractivase were compared to explain the differential binding to collagen and MAJar 3. Thereby, we pinpointed a motif within the Da disintegrin subdomain located opposite to the catalytic domain. Jararhagin binds to both collagen I and IV in a triple helix-dependent manner and inhibited in vitro fibrillogenesis. The jararhagin-collagen complex retained the catalytic activity of the toxin as observed by hydrolysis of fibrin. Thus, we suggest that binding of hemorrhagic SVMPs to collagens I and IV occurs through a motif located in the Da subdomain. This allows accumulation of toxin molecules at the site of injection, close to capillary vessels, where their catalytic activity leads to a local hemorrhage. Toxins devoid of this motif would be more available for vascular internalization leading to systemic pro-coagulant effects. This reveals a novel function of the disintegrin domain in hemorrhage formation.


Asunto(s)
Colágeno/efectos de los fármacos , Venenos de Crotálidos/toxicidad , Metaloendopeptidasas/toxicidad , Secuencia de Aminoácidos , Animales , Sitios de Unión , Colágeno/química , Colágeno/metabolismo , Venenos de Crotálidos/química , Venenos de Crotálidos/metabolismo , Metaloendopeptidasas/química , Metaloendopeptidasas/metabolismo , Modelos Moleculares , Datos de Secuencia Molecular , Inhibidores de Agregación Plaquetaria/química , Inhibidores de Agregación Plaquetaria/metabolismo , Veneno de Bothrops Jararaca
9.
J Pathol ; 211(4): 420-30, 2007 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-17236170

RESUMEN

The histogenesis of sarcomatoid urothelial carcinoma, a rare neoplasm with bidirectional epithelial and mesenchymal differentiation, has been a matter of controversy. To clarify its origin, we analysed the status of X-chromosome inactivation in sarcomatoid urothelial carcinomas from 10 female patients and examined losses of heterozygosity (LOH) in these specimens and in additional 20 tumours from male patients. Six polymorphic microsatellite markers where genetic alterations occur frequently in early or advanced stages of urothelial carcinomas, including D3S3050, D8S261, IFNA, D9S177, D11S569 and TP53, were investigated in the current study. The identical pattern of non-random X-chromosome inactivation in both carcinomatous and sarcomatous components was identified in five of eight informative female patients, and the remaining three informative cases showed a random, but concordant, pattern of X-chromosome inactivation. The concordant X-chromosome inactivation results in all eight informative cases support the concept of a monoclonal origin of both components of this biphasic neoplasm. Among the tumours demonstrating loss of heterozygosity, high incidences of an identical pattern of allelic loss between carcinomatous and sarcomatous components were identified in genetic alterations associated with early carcinogenesis: 86% at D8S261, 78% at D11S569, 75% at D9S177 and 57% at IFNA. In contrast, concordant LOH patterns were less frequently observed for microsatellites related to advanced carcinogenesis: only 40% at D3S3050 and 40% at TP53. The significant overlap of loss of heterozygosity supports a monoclonal cell origin and suggests that clonal divergence may occur during tumour progression and differentiation. Divergent patterns of discordant allelic loss of microsatellite markers imply that heterogeneous pathogenetic pathways may exist in the evolution of this enigmatic neoplasm.


Asunto(s)
Carcinoma de Células Transicionales/genética , Neoplasias de la Vejiga Urinaria/genética , Inactivación del Cromosoma X/genética , Adulto , Anciano , Anciano de 80 o más Años , Carcinoma de Células Transicionales/patología , Transformación Celular Neoplásica/genética , Cromosomas Humanos X/genética , Células Clonales/fisiología , Femenino , Humanos , Pérdida de Heterocigocidad/genética , Masculino , Microdisección/métodos , Repeticiones de Microsatélite/genética , Persona de Mediana Edad , Estudios Retrospectivos , Sarcoma/genética , Sarcoma/patología , Vejiga Urinaria/patología , Neoplasias de la Vejiga Urinaria/patología , Urotelio/patología
10.
J Clin Pathol ; 59(3): 285-8, 2006 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-16505280

RESUMEN

AIMS: Pim-1 is a serine/threonine kinase that has been shown to play an integral role in the development of a number of human cancers, such as haematolymphoid malignancies. Recently, evidence has shown Pim-1 to be important in prostatic carcinogenesis. In order to further our understanding of its role in prostate cancer, we investigated Pim-1 expression in normal, premalignant, and malignant prostate tissue. METHODS: Using immunohistochemistry, Pim-1 expression was analysed in prostate tissue from 120 radical prostatectomy specimens. In each case, Pim-1 staining was evaluated in benign prostatic epithelium, high grade prostatic intraepithelial neoplasia (PIN), and prostatic adenocarcinoma. The number of positively staining cells was estimated, and the intensity of staining was scored on a scale of 0 to 3+. RESULTS: Pim-1 immunoreactivity was identified in 120 cases (100%) of adenocarcinoma, 120 cases (100%) of high grade PIN, and 62 cases (52%) of benign glands. The number of cells staining in benign epithelium (mean 34%) was much lower than that in high grade PIN (mean 80%; p<0.0001) or adenocarcinoma (mean, 84%; p<0.0001). There was no significant difference between high grade PIN and adenocarcinoma in the percentage of cells staining positively for Pim-1 (p = 0.34). The staining intensity for Pim-1 was significantly lower in benign prostatic epithelium than in PIN and adenocarcinoma (p<0.001). There was no statistically significant correlation between the level of Pim-1 expression and Gleason score, patient age, tumour stage, lymph node metastasis, perineural invasion, vascular invasion, surgical margin status, extraprostatic extension, or seminal vesicle invasion. CONCLUSIONS: Pim-1 expression is elevated in PIN and prostatic adenocarcinoma compared with benign prostatic epithelium. This finding suggests that upregulation of Pim-1 may play a role in prostatic neoplasia.


Asunto(s)
Adenocarcinoma/química , Biomarcadores de Tumor/análisis , Neoplasias de la Próstata/química , Proteínas Proto-Oncogénicas c-pim-1/análisis , Adenocarcinoma/cirugía , Anciano , Análisis de Varianza , Progresión de la Enfermedad , Humanos , Masculino , Persona de Mediana Edad , Estadificación de Neoplasias , Prostatectomía , Hiperplasia Prostática/metabolismo , Hiperplasia Prostática/cirugía , Neoplasia Intraepitelial Prostática/química , Neoplasia Intraepitelial Prostática/cirugía , Neoplasias de la Próstata/cirugía , Sensibilidad y Especificidad
11.
Allergy ; 57(12): 1159-64, 2002 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-12464044

RESUMEN

BACKGROUND: To gain insight into the mechanisms responsible for tissue neutrophil immigration in sinusitis, primary nasal fibroblasts are analyzed for synthesizing and delivering neutrophil chemokines. METHODS: Primary nasal fibroblast cell culture was treated with tumor necrosis factor (TNF)-alpha concentrations of 20 and 200 ng/ml for 2, 8, 24 and 72 h. Chemokine concentrations in supernatants were determined by enzyme-linked immunoassay (ELISA) and chemokine mRNA expression in fibroblasts was measured by reverse transcriptase polymerase chain reaction (RT-PCR). Biological chemotactic activity was identified by three-step high-performance liquid chromatography (HPLC) and by bioassay measuring neutrophil chemotaxis in a single Boyden chamber system. RESULTS: Interleukin (IL)-8 and growth-related oncogene (GRO)-alpha were induced in nasal fibroblast culture by proinflammatory stimulus. After 24 h of stimulation neutrophil chemotactic activity only was detected for IL-8. Granulocyte chemotactic protein (GCP)-2 mRNA was already significantly up-regulated after 2 h of stimulation. CONCLUSION: Induction of IL-8 protein dominates chemokine synthesis 24 and 72 h after stimulation, whereas induction of GCP-2 mRNA seems to have a role in the early phase after 2 h of exposition with TNF-alpha.


Asunto(s)
Quimiocinas CXC/metabolismo , Fibroblastos/metabolismo , Mucosa Nasal/citología , Mucosa Nasal/metabolismo , Neutrófilos/metabolismo , Péptidos Catiónicos Antimicrobianos , Proteínas Sanguíneas/farmacología , Proteínas Portadoras/farmacología , Movimiento Celular/efectos de los fármacos , Movimiento Celular/inmunología , Células Cultivadas , Quimiocina CXCL1 , Quimiocinas/biosíntesis , Quimiocinas/inmunología , Quimiocinas CXC/inmunología , Factores Quimiotácticos/biosíntesis , Factores Quimiotácticos/inmunología , Cromatografía , Relación Dosis-Respuesta a Droga , Ensayo de Inmunoadsorción Enzimática , Fibroblastos/inmunología , Humanos , Péptidos y Proteínas de Señalización Intercelular/biosíntesis , Péptidos y Proteínas de Señalización Intercelular/inmunología , Interleucina-8/biosíntesis , Interleucina-8/inmunología , Mucosa Nasal/inmunología , Neutrófilos/inmunología , Reacción en Cadena de la Polimerasa , ARN Mensajero/efectos de los fármacos , ARN Mensajero/inmunología , ARN Mensajero/metabolismo , Estimulación Química , Factores de Tiempo , Factor de Necrosis Tumoral alfa/administración & dosificación , Regulación hacia Arriba/efectos de los fármacos , Regulación hacia Arriba/fisiología
12.
Am J Surg Pathol ; 25(10): 1231-6, 2001 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-11688456

RESUMEN

Renal angiomyolipoma is a benign neoplasm composed of variable proportions of blood vessels, smooth muscle, and adipose tissue. Smooth muscle, adipose tissue, blood vessels, and adjacent normal kidney tissue were separately microdissected from sections prepared from formalin-fixed, paraffin-processed tissues from angiomyolipomas from 18 women. X chromosome inactivation analysis using the methylation pattern at exon 1 of the human androgen receptor gene on chromosome Xq11-12 was used to study the clonal origin of each component. Nonrandom inactivation of X chromosomes was found in six of the 15 informative tumors. The smooth muscle and adipose tissue showed differing patterns of nonrandom inactivation of X chromosomes in five angiomyolipomas and the same pattern of nonrandom inactivation of X chromosomes in one. Samples from the blood vessels showed random inactivation of X chromosomes in all informative cases. Our data showed that the adipose tissue and smooth muscle cells of renal angiomyolipoma are both monoclonal but may arise independently. The coexistence of tumor subclones with morphologic heterogeneity can lead to the formation of a clinically detectable tumor.


Asunto(s)
Angiomiolipoma/genética , Neoplasias Renales/genética , Tejido Adiposo/citología , Tejido Adiposo/metabolismo , Angiomiolipoma/metabolismo , Angiomiolipoma/patología , Vasos Sanguíneos/citología , Vasos Sanguíneos/metabolismo , Células Clonales , Clonación Molecular , Cartilla de ADN/química , ADN de Neoplasias/análisis , Disección , Femenino , Humanos , Neoplasias Renales/metabolismo , Neoplasias Renales/patología , Micromanipulación , Persona de Mediana Edad , Músculo Liso/citología , Músculo Liso/metabolismo , Reacción en Cadena de la Polimerasa , Receptores Androgénicos/genética , Receptores Androgénicos/metabolismo , Aberraciones Cromosómicas Sexuales , Cromosoma X
14.
Am J Surg Pathol ; 25(11): 1451-7, 2001 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-11684965

RESUMEN

Metanephric neoplasms are uncommon renal tumors that arise in both children and adults. They may be composed of small epithelial cells or benign stroma, or both, and are termed metanephric adenoma, metanephric stromal tumor, or metanephric adenofibroma, respectively. Thus far, these tumors have been known for their benign behavior. We present the case of a 21-year-old woman who developed a neoplasm composed of a renal epithelial component identical to metanephric adenoma combined with a malignant spindle cell sarcoma. The epithelial component was positive for pankeratin AE1/3, whereas the sarcomatous component was negative for epithelial markers and positive for vimentin, CD34, and CD117. No smooth muscle differentiation was apparent in the sarcoma by immunohistochemistry or ultrastructural analysis. By fluorescent in situ hybridization analysis of the sarcomatous component there was monosomy of the X chromosome, but no apparent variation from the normal diploid pattern for chromosomes 3, 7, 12, and 17. We conclude that the spectrum of metanephric neoplasia should be expanded to include malignant stromal variants, and we propose the term "metanephric adenosarcoma" for the present case.


Asunto(s)
Adenosarcoma/secundario , Neoplasias Renales/patología , Sarcoma/secundario , Adenosarcoma/química , Adenosarcoma/terapia , Adulto , Antígenos de Neoplasias/análisis , Biomarcadores de Tumor/análisis , Terapia Combinada , ADN de Neoplasias/análisis , Resultado Fatal , Femenino , Humanos , Inmunofenotipificación , Hibridación Fluorescente in Situ , Neoplasias Renales/química , Neoplasias Renales/terapia , Sarcoma/química , Sarcoma/genética , Sarcoma/terapia , Cromosoma X
15.
Mod Pathol ; 14(10): 963-8, 2001 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-11598165

RESUMEN

The ability to predict cancer progression may help the clinical management of patients with penile squamous cell carcinoma. We studied 22 cases of squamous cell carcinoma of the penis diagnosed between 1989 and 1998. The depth of invasion was measured from the basement membrane of the squamous epithelium to the deepest invasive cancer cells. Cancer progression was defined as the development of lymph node metastasis or distant metastasis. The mean patient age was 63 years and the mean follow-up was 28 months. Ten patients developed cancer progression. The mean depth of invasion among patients with cancer progression was 9.8 mM, as compared to the mean depth of invasion of 4.0 mM among those patients without cancer progression (P =.02). Vascular invasion was also predictive of cancer progression (P =.02). Metastases developed in the majority (6 out of 7) of cases invading more than 6 mM, but developed only in a minority (4 out of 15) of cases invading 6 mM or less. We conclude that depth of invasion and vascular invasion are significant predictors of cancer progression for penile squamous cell carcinoma.


Asunto(s)
Carcinoma de Células Escamosas/patología , Neoplasias del Pene/patología , Adulto , Anciano , Anciano de 80 o más Años , Carcinoma de Células Escamosas/irrigación sanguínea , Humanos , Metástasis Linfática , Masculino , Persona de Mediana Edad , Invasividad Neoplásica , Estadificación de Neoplasias , Neovascularización Patológica/patología , Neoplasias del Pene/irrigación sanguínea , Pronóstico
16.
Mol Biol Cell ; 12(10): 2975-86, 2001 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-11598185

RESUMEN

The urokinase receptor (uPAR) is linked to cellular migration through its capacity to promote pericellular proteolysis, regulate integrin function, and mediate cell signaling in response to urokinase (uPA) binding. The mechanisms for these activities remain incompletely defined, although uPAR was recently identified as a cis-acting ligand for the beta2 integrin CD11b/CD18 (Mac-1). Here we show that a major beta1 integrin partner for uPAR/uPA signaling is alpha3. In uPAR-transfected 293 cells uPAR complexed (>90%) with alpha3beta1 and antibodies to alpha3 blocked uPAR-dependent vitronectin (Vn) adhesion. Soluble uPAR bound to recombinant alpha3beta1 in a uPA-dependent manner (K(d) < 20 nM) and binding was blocked by a 17-mer alpha3beta1 integrin peptide (alpha325) homologous to the CD11b uPAR-binding site. uPAR colocalized with alpha3beta1 in MDA-MB-231 cells and uPA (1 nM) enhanced spreading and focal adhesion kinase phosphorylation on fibronectin (Fn) or collagen type I (Col) in a pertussis toxin- and alpha325-sensitive manner. A critical role of alpha3beta1 in uPA signaling was verified by studies of epithelial cells from alpha3-deficient mice. Thus, uPAR preferentially complexes with alpha3beta1, promoting direct (Vn) and indirect (Fn, Col) pathways of cell adhesion, the latter a heterotrimeric G protein-dependent mechanism of signaling between alpha3beta1 and other beta1 integrins.


Asunto(s)
Movimiento Celular/fisiología , Integrina beta1/metabolismo , Integrinas/metabolismo , Receptores de Superficie Celular/metabolismo , Activador de Plasminógeno de Tipo Uroquinasa/metabolismo , Sitios de Unión/fisiología , Antígenos CD18 , Línea Celular , Movimiento Celular/efectos de los fármacos , Colágeno/metabolismo , Fibronectinas/metabolismo , Proteínas de Unión al GTP Heterotriméricas/química , Humanos , Integrina alfa3beta1 , Integrinas/química , Integrinas/genética , Antígeno de Macrófago-1/genética , Antígeno de Macrófago-1/metabolismo , Pruebas de Precipitina , Receptores del Activador de Plasminógeno Tipo Uroquinasa , Proteínas Recombinantes/metabolismo , Homología de Secuencia , Transducción de Señal , Células Tumorales Cultivadas , Activador de Plasminógeno de Tipo Uroquinasa/farmacología , Familia-src Quinasas/química
17.
J Natl Cancer Inst ; 93(15): 1147-52, 2001 Aug 01.
Artículo en Inglés | MEDLINE | ID: mdl-11481386

RESUMEN

BACKGROUND: Molecular data suggest that peritoneal tumors in women with advanced-stage ovarian papillary serous adenocarcinoma are monoclonal in origin. Whether the same is true for ovarian tumors of low malignant potential is not known. We compared peritoneal and ovarian tumors from women with advanced-stage ovarian papillary serous tumors of low malignant potential to determine whether the peritoneal tumors arose from the same clone as the ovarian tumors. METHODS: We studied the clonality of 73 peritoneal and ovarian tumors from 18 women with advanced-stage ovarian papillary serous tumors of low malignant potential. Formalin-fixed, paraffin-embedded tumors and representative normal tissues were sectioned and stained with hematoxylin-eosin, representative sections from separate tumors were manually microdissected, genomic DNA was extracted from the microdissected tumors, and the polymerase chain reaction was used to amplify a CAG polymorphic site in the human androgen receptor locus on the X chromosome to determine the inactivation pattern of the X chromosome and the clonality of the tumors. RESULTS: The pattern of X-chromosome inactivation could be determined from the tumors of 13 of 18 patients. Of the 13 patients, seven (54%) had nonrandom inactivation of the X chromosome, and six of the seven had different inactivation patterns in the peritoneal and ovarian tumors. Three of these patients also had different patterns of nonrandom X-chromosome inactivation in tumors from each ovary. The remaining six patients had random patterns of X-chromosome inactivation in the peritoneal and ovarian tumors. CONCLUSIONS: Our data suggest that peritoneal and ovarian tumors of low malignant potential arise independently.


Asunto(s)
Adenocarcinoma Papilar/genética , Neoplasias Ováricas/genética , Neoplasias Ováricas/patología , Neoplasias Peritoneales/genética , Cromosoma X/genética , Adenocarcinoma Papilar/secundario , Adulto , Anciano , Anciano de 80 o más Años , Enzimas de Restricción del ADN/genética , ADN de Neoplasias/análisis , Femenino , Humanos , Metilación , Persona de Mediana Edad , Neoplasias Peritoneales/secundario , Reacción en Cadena de la Polimerasa , Aberraciones Cromosómicas Sexuales/genética , Expansión de Repetición de Trinucleótido
18.
Hum Pathol ; 32(6): 590-5, 2001 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-11431713

RESUMEN

Whereas papillary renal cell carcinoma is now established as a subtype of renal cell neoplasia, division of these tumors into 2 distinctive morphotypes has been proposed. Type 1 tumors have cells with scanty pale cytoplasm arranged in a single layer on the basement membrane of papillary cores. In these tumors, psammoma bodies and foamy macrophages are frequently seen, and the tumors frequently express cytokeratin 7. Type 2 tumor cells have pseudostratified nuclei and usually have voluminous eosinophilic cytoplasm. Recent studies have supported this subclassification of papillary renal cell carcinoma by demonstrating differing genotypes for type 1 and 2 tumors. To further study the subclassification of papillary renal carcinoma, we compared clinical features, nuclear grade, stage, tumor growth kinetics, and survival in a series of 50 type 1 and 16 type 2 papillary renal cell carcinomas. Comparison of patient age at presentation, sex, and primary tumor size shows no significant difference between the 2 tumor types. Type 1 tumors were of significantly lower Fuhrman grade (P =.0001) and higher Robson stage (P =.009) than type 2 tumors. There was no significant difference when tumors were staged according to the TNM classification. Assessment of tumor growth kinetics showed significantly different mean silver-staining nucleolar organizer region (AgNOR) scores and Ki-67 indices (AgNOR type 1, 3.83, type 2, 7.24, P =.0001; Ki-67 type 1, 3.17%, type 2, 6.01%, P =.0002). Multivariate analysis showed tumor type (P =.03), presence of metastases (P =.04), AgNOR score (P =.001), and Ki-67 index (P =.03) to be independently associated with survival. These results provide evidence of the clinical utility of dividing papillary renal cell carcinomas into 2 types according to histologic characteristics.


Asunto(s)
Carcinoma Papilar/patología , Carcinoma de Células Renales/patología , División Celular , Neoplasias Renales/patología , Tasa de Supervivencia , Adulto , Anciano , Anciano de 80 o más Años , Carcinoma Papilar/clasificación , Carcinoma Papilar/mortalidad , Carcinoma de Células Renales/clasificación , Carcinoma de Células Renales/mortalidad , Núcleo Celular/patología , Citoplasma/patología , Femenino , Humanos , Queratina-7 , Queratinas/análisis , Antígeno Ki-67/análisis , Neoplasias Renales/clasificación , Neoplasias Renales/mortalidad , Cinética , Macrófagos/patología , Masculino , Persona de Mediana Edad , Metástasis de la Neoplasia , Estadificación de Neoplasias , Región Organizadora del Nucléolo/patología , Tinción con Nitrato de Plata
20.
Hum Pathol ; 32(5): 513-20, 2001 May.
Artículo en Inglés | MEDLINE | ID: mdl-11381370

RESUMEN

Mixed epithelial and stromal tumor of the kidney is a recently recognized neoplasm that occurs almost exclusively in perimenopausal women. Because it frequently contains areas of smooth muscle in which epithelial structures are embedded, some have concluded that it is the adult form of congenital mesoblastic nephroma. Others have concluded that the morphology and epidemiology of mixed epithelial and stromal tumor indicate that it is unrelated to congenital mesoblastic nephroma. Although the genetic alterations of mixed epithelial and stromal tumor have not been previously elucidated, much is known about the genetic alterations of cellular congenital mesoblastic nephroma. The present study was undertaken to determine if mixed epithelial and stromal tumors have any of the genetic alterations recognized as typical of cellular congenital mesoblastic nephroma. RNA extraction was performed on formalin-fixed, paraffin-embedded tissue from 7 mixed epithelial and stromal tumors followed by reverse-transcription polymerase chain reaction to detect the ETV6-NTRK3 gene fusion. Fluorescent in situ hybridization with centromere-specific probes for chromosomes 8, 11, and 17 was performed to evaluate polyploidy of these chromosomes in 11 cases of mixed epithelial and stromal tumor. None of the mixed epithelial and stromal tumors showed any of these genetic alterations. We conclude that mixed epithelial and stromal tumor of the kidney lacks the genetic alterations typical of cellular congenital mesoblastic nephroma, is unrelated to it, and the appellation "adult mesoblastic nephroma" should not be used for these tumors.


Asunto(s)
Células Epiteliales/patología , Neoplasias Renales/genética , Nefroma Mesoblástico/congénito , Nefroma Mesoblástico/genética , Proteínas Represoras , Células del Estroma/patología , Adulto , Anciano , Cromosomas Humanos Par 11 , Cromosomas Humanos Par 17 , Cromosomas Humanos Par 8 , Proteínas de Unión al ADN/genética , Femenino , Humanos , Hibridación Fluorescente in Situ , Neoplasias Renales/patología , Menopausia , Persona de Mediana Edad , Proteínas de Fusión Oncogénica , Ploidias , Proteínas Proto-Oncogénicas c-ets , Receptor trkC/genética , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Factores de Transcripción/genética , Translocación Genética , Proteína ETS de Variante de Translocación 6
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA